A Response to ‘Another Legislative Attempt to Revive Gene Patenting’
Including purified and isolated materials as eligible subject matter under 35 U.S.C. § 101 can benefit patients, researchers, and innovation.
Gene Patenting
-
Read more: A Response to ‘Another Legislative Attempt to Revive Gene Patenting’ -
Read more: Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna? Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this research.
-
Read more: The Civil Rights Challenge to Gene Patenting The Civil Rights Challenge to Gene Patenting
The ACLU mounted an unprecedented challenge the entire practice of gene patenting in America. And, against the odds, they won.
-
Read more: What Ever Happened to NIH’s “Fair Pricing” Clause? What Ever Happened to NIH’s “Fair Pricing” Clause?
It remains to be seen whether Congress or the Administration adopt more decisive measures toward the control of drug prices than they have in the past.
-
Read more: Video Now Available: “Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology” Video Now Available: “Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology”
In case you missed it live on Monday evening, video from the Petrie-Flom Center’s event “Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology” (co-sponsored by the Broad Institute) is now available here. 09/27/13 UPDATE: Our intern Fatima Mirza also wrote up this summary: At this event, a distinguished panel of law and…